A 104-Week, Open-Label, Single-Group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH).

Trial Profile

A 104-Week, Open-Label, Single-Group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms REACH
  • Most Recent Events

    • 26 May 2010 Planned number of patients (60) added as reported by ClinicalTrials.gov record.
    • 29 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top